BIOPOR Stock Overview
An in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
BioPorto A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | DKK 1.72 |
52 Week High | DKK 2.85 |
52 Week Low | DKK 1.21 |
Beta | 1.17 |
11 Month Change | -1.71% |
3 Month Change | -12.05% |
1 Year Change | -21.90% |
33 Year Change | -33.26% |
5 Year Change | -40.82% |
Change since IPO | -99.25% |
Recent News & Updates
Recent updates
We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely
Oct 22We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully
Dec 25We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully
Jun 28We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely
Feb 27Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth
Oct 19We're Keeping An Eye On BioPorto's (CPH:BIOPOR) Cash Burn Rate
Jun 15Is BioPorto (CPH:BIOPOR) In A Good Position To Deliver On Growth Plans?
Feb 17Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation
Oct 16Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth
May 28BioPorto A/S' (CPH:BIOPOR) Path To Profitability
Mar 01We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully
Jan 24A Look At BioPorto's (CPH:BIOPOR) CEO Remuneration
Dec 20The BioPorto A/S (CPH:BIOPOR) Analysts Have Been Trimming Their Sales Forecasts
Nov 23BioPorto A/S (CPH:BIOPOR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Nov 21Shareholder Returns
BIOPOR | DK Biotechs | DK Market | |
---|---|---|---|
7D | -1.0% | 2.6% | -0.3% |
1Y | -21.9% | -0.9% | 15.3% |
Return vs Industry: BIOPOR underperformed the Danish Biotechs industry which returned -0.9% over the past year.
Return vs Market: BIOPOR underperformed the Danish Market which returned 15.3% over the past year.
Price Volatility
BIOPOR volatility | |
---|---|
BIOPOR Average Weekly Movement | 6.0% |
Biotechs Industry Average Movement | 7.6% |
Market Average Movement | 4.3% |
10% most volatile stocks in DK Market | 11.5% |
10% least volatile stocks in DK Market | 2.6% |
Stable Share Price: BIOPOR has not had significant price volatility in the past 3 months compared to the Danish market.
Volatility Over Time: BIOPOR's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1917 | 36 | Peter Eriksen | bioporto.com |
BioPorto A/S, an in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated clinical chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. BioPorto A/S was incorporated in 1917 and is based in Hellerup, Denmark.
BioPorto A/S Fundamentals Summary
BIOPOR fundamental statistics | |
---|---|
Market cap | DKK 739.87m |
Earnings (TTM) | -DKK 61.30m |
Revenue (TTM) | DKK 34.91m |
21.2x
P/S Ratio-12.1x
P/E RatioIs BIOPOR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BIOPOR income statement (TTM) | |
---|---|
Revenue | DKK 34.91m |
Cost of Revenue | DKK 10.05m |
Gross Profit | DKK 24.86m |
Other Expenses | DKK 86.16m |
Earnings | -DKK 61.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.14 |
Gross Margin | 71.22% |
Net Profit Margin | -175.62% |
Debt/Equity Ratio | 0% |
How did BIOPOR perform over the long term?
See historical performance and comparison